Mental health
Paliperidone
Brand: Paljuna Monthly
PBAC's latest decision on Paliperidone: Recommended (2025). Considered for Maintenance treatment of schizophrenia in adults.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
2007 → 2025
Eligible population
Adults with schizophrenia requiring maintenance treatment with paliperidone once-monthly long-acting injection.
- Therapy area
- Mental health
- Line of therapy
- Any
- Evidence base
- Cost-minimisation
- Primary endpoint
- Cost-minimisation
- Comparator
- Invega Sustenna
- Economic model
- Cost-minimisation
- ICER note
- Cost-minimisation analysis; no ICER calculated. Sponsor confirmed cost-minimisation at equivalent price per injection to Invega Sustenna.
Submission history
- Nov 2007: Recommended · Authority Required
- Jul 2025: Recommended · Authority Required
Similar precedents
Open on full dashboard →